Plasma HIV-1 and HIV-2 RNA Quantification for HIV Infection
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage and clinical use of plasma HIV-1 and HIV-2 RNA quantification (viral load) testing for diagnosis, monitoring, and management of HIV infection for Blue Cross Blue Shield - Tennessee members.
No material clinical or coverage changes in this revision.
Coverage Criteria — When Plasma HIV RNA Quantification Is Covered
inv-01: Covered Indications
Covered when ALL of the following are met
Coverage is dependent on individual benefit plan and clinical indication.
inv-02: Frequency / Monitoring
Monitoring frequency guidance (DHHS)
Follow current DHHS/IDSA/IAS/BHIVA guidance for specific intervals and adjustments based on clinical context.
inv-03: Assay and Interpretation Criteria
Interpretation and assay considerations
Interpret low-level results with caution; consistency of assay platform is preferred for longitudinal follow-up.
inv-04: Confirmation Requirements
Diagnostic confirmation in special situations
Collect a new specimen for confirmatory testing and document results prior to starting therapy when feasible.
inv-05: HIV-2 Considerations
HIV-2 specific points
Consider specialized testing and expert consultation for HIV-2 management.
inv-06: Diagnosis of acute HIV infection
Covered when ALL of the following are met
Repeat low-positive RNA (<3,000 copies/mL) on a new blood specimen to confirm; document repeat testing prior to treatment when feasible.
inv-07: Testing in persons taking PrEP
Covered when ALL of the following are met
Confirmatory testing aims to avoid inappropriate treatment changes and false-positive diagnoses.
inv-08: Viral load monitoring during ART
Covered when ALL of the following are met
Consider adherence, drug interactions, and resistance testing in cases of suboptimal response.
inv-09: Pregnancy monitoring and delivery planning
Covered when ALL of the following are met
Repeat testing should be available to inform delivery planning even in the absence of identified risk factors.
Use of plasma HIV-1 or HIV-2 RNA quantification as a routine diagnostic method is limited. Per the policy limitations, viral quantification is appropriate for prognostic purposes including baseline determination, periodic monitoring, and monitoring of response to therapy, but use as a general diagnostic test method is not indicated except in the specific situations outlined elsewhere in this policy (for example, evaluation of acute infection or equivocal serologic results).
Laboratory-developed tests (LDTs) for HIV RNA quantification are commonly performed in clinical laboratories and are regulated under CLIA as high-complexity tests. These LDTs are not approved or cleared by the FDA, but FDA clearance is not required for clinical use; the policy excerpt does not categorically prohibit LDT use, though it notes their regulatory status and the need for appropriate validation and oversight.
The referenced listings and literature citations in this policy do not state additional explicit exclusions beyond those described in the limitations and coverage sections. Clinicians should follow the policy’s specified covered indications and the listed limitations when determining appropriateness.
Viral load assays intended for quantification should not be used solely as a standalone diagnostic test except in the specific covered circumstances described in this policy. Use of quantitative HIV RNA outside those indicated purposes (baseline, monitoring therapy, prognostic use, or the other exceptions in the policy) is considered outside the intended use and may be denied.
Routine quarterly viral load testing in patients with durable viral suppression should be avoided unless there is a clinical indication. The HIV Medicine Association (HIVMA) / Choosing Wisely guidance specifically advises against quarterly viral load testing for stably suppressed patients unless clinically indicated; monitoring intervals otherwise follow DHHS/IDSA recommendations.
Within the provided citation entries there are no discrete statements explicitly labeled as ‘not medically necessary’ beyond the policy’s general limitation that viral quantification used solely as a diagnostic test outside specified indications is not the intended use. Review the policy’s Covered Indications and Limitations for determinations of medical necessity.
Coding, Thresholds, and Assay References
| No codes listed |
Provider Actions, Documentation, and Authorization Guidance
Obtain viral load only for specified clinical indications
Baseline and monitoring plasma HIV-1 or HIV-2 RNA quantification meet coverage criteria only when a listed clinical indication is present (for example: persistent borderline/equivocal serologic reactivity in an at‑risk person; signs/symptoms of acute retroviral syndrome in an at‑risk person; monitoring disease progression; monitoring response to ART; infants <18 months born to HIV‑positive mothers; predicting maternal–fetal transmission). Authorization should align with the member's benefit coverage and the specified clinical situations.
- Examples of covered clinical situations are explicitly enumerated in the policy (see list above).
- Coverage for predicting maternal–fetal transmission is specifically noted.
No prior authorization specified for assays in policy text
The document does not specify any prior authorization program or explicit PA forms for use of RT‑PCR or Ag/Ab assays; FDA‑approved RT‑PCR and antigen/antibody assays are described for diagnostic and monitoring use but no PA requirement is stated.
- All three primary RT‑PCR tests for HIV‑1 have FDA approval (Abbott RealTime, COBAS TaqMan, Aptima).
- The policy text lists assays and FDA summaries but does not direct a prior authorization process.
Policy cites evidence sources but does not define PA rules
The policy's evidence and reference listing do not establish specific prior authorization requirements or criteria beyond coverage tied to clinical indications and member benefits.
- Reference list and guidance sources are cited, but no explicit PA criteria are provided in these sections.
Order resistance testing when viral suppression is not achieved
If a patient fails to achieve viral suppression, perform resistance testing to guide selection of alternative antiretroviral regimens; monitor frequency and additional evaluations based on adherence and clinical circumstances.
- Assess adherence, drug exposure, and interactions as part of the evaluation for suboptimal response.
- Resistance testing is recommended to aid in selecting an alternative regimen when suppression is not achieved.
Repeat and confirm testing before starting ART in persons on PrEP
For persons taking PrEP with negative antibody testing but a very low‑positive quantitative HIV RNA (<3,000 copies/mL), obtain repeat confirmatory testing (repeat quantitative RNA and antibody differentiation) and ensure results are available before initiating or changing ART.
- Collect a new blood specimen to verify the HIV diagnosis prior to initiating ART.
- Consider HIV DNA testing in rare inconclusive cases when transitioning from PrEP to an ARV regimen.
No step therapy requirements stated
No step therapy requirements (sequenced medication trials or prior‑step conditions) are described in the cited reference listings.
- Policy references clinical guidelines and FDA summaries but does not mandate step therapy sequences.
Document timing of testing and clinical indication per DHHS intervals
Document the timing of viral load testing relative to ART initiation or modification and the clinical indication for testing in the medical record in accordance with DHHS frequency recommendations (entry into care; 2–4 weeks [no later than 8] after ART start; every 3–4 months for first 2 years; every 6 months if stable thereafter; 4–8 weeks after regimen change for toxicity; more frequent if detectable viremia).
- Record why the test was ordered (baseline, monitoring ART response, acute infection, pregnancy planning, infant testing, etc.).
- Note dates of ART initiation or modification to support timing of follow‑up testing.
Record confirmatory testing and repeat specimen collection for low‑positive or discordant results
When a positive quantitative HIV RNA occurs with negative or indeterminate antibody tests, document repeat quantitative RNA testing or subsequent seroconversion testing on a new specimen before initiating ART; for low‑positive RNA (<3,000 copies/mL) specifically, repeat testing on a new blood specimen is required to confirm infection.
- Ensure repeat test results are available prior to starting ART when feasible.
- If repeat testing remains inconclusive, document consideration of HIV DNA testing as appropriate.
Attach cited FDA summaries and guideline references to support test selection
References and regulatory summaries (FDA assay summaries and DHHS/clinical guidelines) cited in the policy should be included in supporting documentation to justify test selection and medical necessity.
- Include FDA assay summary citations when using a specific FDA‑approved assay for diagnosis or monitoring.
- Reference DHHS guideline sections when documenting timing and rationale for testing.
Ensure testing is for covered clinical indications to avoid denial
Viral quantification is intended primarily for baseline determination, periodic monitoring, prognosis, and monitoring response to therapy; requests to use viral quantification solely as a general diagnostic test outside these indications may be denied.
- Use as a diagnostic method is limited except in the specified situations (e.g., acute infection, equivocal serology).
- Measuring viral load outside covered indications should be avoided or justified in the record.
Collect a new specimen to confirm positive Ag/Ab or RNA before ART
When an initial reactive Ag/Ab or positive HIV RNA result is obtained with negative or indeterminate antibody differentiation, collect a new blood specimen and confirm the positive result on that new specimen prior to initiating ART to avoid inappropriate treatment decisions.
- Policy explicitly states a new blood specimen should be collected to verify diagnosis before starting ART.
- Repeat quantitative or qualitative RNA and repeat antibody testing are recommended for confirmation.
No explicit denial triggers specified in cited references
The reference citations do not list explicit denial triggers beyond coverage‑indication mismatches; they serve to supply supporting literature and regulatory documents rather than a discrete list of denial criteria.
- No specific denial conditions (e.g., exact CPT codes or administrative PA denials) are specified in these references.
Background and Context
HIV is an RNA retrovirus that causes progressive CD4 cell decline and increased susceptibility to opportunistic infections. Quantitative plasma HIV RNA (viral load) measurement is the primary laboratory marker used to assess disease burden and response to antiretroviral therapy; the policy ties coverage to specific clinical indications such as baseline assessment, monitoring after ART initiation/modification, evaluation of suspected acute infection, infant testing, and management during pregnancy.
Definitions and Abbreviations
Policy Revision History
Policy adopted (Avalon policy recommendation) and became effective for plasma HIV-1 and HIV-2 RNA quantification coverage criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.